您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2020, Vol. 1 ›› Issue (8): 88-94.doi: 10.6040/j.issn.1671-7554.0.2020.0604

• 脑科学与类脑智能研究专题 • 上一篇    下一篇

靶向小类泛素化修饰的胶质瘤治疗新策略

陈安静1,2,*(),张训1,2   

  1. 1. 山东大学齐鲁医院神经外科，山东大学脑与类脑科学研究院, 山东 济南 250012
    2. 山东省脑功能重构重点实验室, 山东 济南 250012
  • 收稿日期:2020-04-15 出版日期:2020-08-01 发布日期:2020-08-07
  • 通讯作者: 陈安静 E-mail:chenaj@sdu.edu.cn
  • 作者简介:陈安静，研究员，山东省“泰山学者”青年专家，山东大学生物化学与分子生物学博士。研究方向为SUMO化和泛素化修饰调控脑胶质瘤恶性进展与转化的分子机制。以项目负责人身份主持国家自然科学基金、中国博士后基金面上项目、山东省重点研发计划和山东省自然科学基金等。累计发表SCI收录论文40篇，以通讯作者和第一作者在《Clinical Cancer Research》《Journal of Virology》等期刊发表文章。曾获山东省优秀科技创新成果奖、山东省医学科技奖和山东大学学生“五·四”青年科学奖等。
  • 基金资助:
    山东省泰山学者人才工程(tsqn201909173);中国博士后基金(2018M642666)

The new strategies of targeting SUMOylation in the treatment of glioma

Anjing CHEN1,2,*(),Xun ZHANG1,2   

  1. 1. Department of Neurosurgery, Qilu Hospital of Shandong University and Institute of Brain and Brain-Inspired Science, Shandong University, Jinan 250012, Shandong, China
    2. Shandong Key Laboratory of Brain Function Remodeling, Jinan 250012, Shandong, China
  • Received:2020-04-15 Online:2020-08-01 Published:2020-08-07
  • Contact: Anjing CHEN E-mail:chenaj@sdu.edu.cn

RichHTML

9

PDF (PC)

1439

摘要：

蛋白质的小类泛素(SUMO)化修饰(SUMOylation)是一种动态的翻译后修饰，涉及了细胞一系列的生理过程。值得注意的是，SUMO化也在多种癌症病理过程中发挥重要作用，其中包括严重危害人类健康的脑胶质瘤。本文回顾分析SUMO化修饰与胶质瘤相关的核心文献，着重探究SUMO化修饰过程中的关键靶点，可望作为胶质瘤治疗有潜力的新方法，为其精准靶向治疗提供新的策略。

关键词: 胶质瘤, 小类泛素化修饰, 恶性进展, 靶向治疗

Abstract:

Small ubiquitin-like modification (SUMOylation), a dynamic process of post-translational modification, involves a series of physiological changes within the cells. SUMOylation also plays an important role in the pathological progresses of a number of cancers including the fatal disease, glioma. In this essay, we reviewed the key aspects of SUMOylation in association with glioma from the literatures and highlighted that some potential targets were expected to be therapeutic strategies in the treatment of glioma.

Key words: Glioma, SUMOylation, Malignant progression, Targeted therapy

中图分类号: 

  • R456

图1

胶质瘤SUMO化修饰增强参与调节多重细胞过程并导致恶性进展"

1 Stupp R , Hegi ME , Mason WP , et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORTC-NCIC trial[J]. Lancet Oncol, 2009, 10 (5): 459- 466.
doi: 10.1016/S1470-2045(09)70025-7
2 Polivka JJr , Polivka J , Holubec L , et al. Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme[J]. Anticancer Res, 2017, 37 (1): 21- 33.
3 Mahajan R , Delphin C , Guan T , et al. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2[J]. Cell, 1997, 88 (1): 97- 107.
doi: 10.1016/S0092-8674(00)81862-0
4 Hendriks I A , Vertegaal A C . A comprehensive compilation of SUMO proteomics[J]. Nat Rev Mol Cell Biol, 2016, 17 (9): 581- 595.
doi: 10.1038/nrm.2016.81
5 Eifler K , Vertegaal ACO . SUMOylation-mediated regulation of cell cycle progression and cancer[J]. Trends Biochem. Sci, 2015, 40 (12): 779- 793.
doi: 10.1016/j.tibs.2015.09.006
6 Bayer P , Arndt A , Metzger S , et al. Structure determination of the small ubiquitin-related modifier SUMO-1[J]. J Mol Biol, 1998, 280 (2): 275- 286.
doi: 10.1006/jmbi.1998.1839
7 Shen Z , Pardington-Purtymun PE , Comeaux JC , et al. UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins[J]. Genomics, 1996, 36 (2): 271- 279.
doi: 10.1006/geno.1996.0462
8 Boddy MN , Howe K , Etkin LD , et al. PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia[J]. Oncogene, 1996, 13 (5): 971- 982.
9 Matunis MJ , Coutavas E , Blobel G . A novel ubiquitin-like modification modulates the partitioning of the Ran-GTPase-activating protein RanGAP1 between the cytosol and the nuclear pore complex[J]. J Cell Biol, 1996, 135 (6 Pt 1): 1457- 1470.
10 Lapenta V , Chiurazzi P , van der Spek P , et al. SMT3A, a human homologue of the S. cerevisiae SMT3 gene, maps to chromosome 21qter and defines a novel gene family[J]. Genomics, 1997, 40 (2): 362- 366.
doi: 10.1006/geno.1996.4556
11 Johnson ES . Protein modification by SUMO[J]. Annu Rev Biochem, 2004, 73: 355- 382.
doi: 10.1146/annurev.biochem
12 Evdokimov E , Sharma P , Lockett SJ , et al. Loss of SUMO1 in mice affects RanGAP1 localization and formation of PML nuclear bodies, but is not lethal as it can be compensated by SUMO2 or SUMO3[J]. J Cell Sci, 2008, 121 (Pt 24): 4106- 4113.
13 Owerbach D , McKay EM , Yeh ET , et al. A proline-90 residue unique to SUMO-4 prevents maturation and sumoylation[J]. Biochem Biophys Res Commun, 2005, 337 (2): 517- 520.
doi: 10.1016/j.bbrc.2005.09.090
14 Hickey CM , Wilson NR , Hochstrasser M . Function and regulation of SUMO proteases[J]. Nat Rev Mol Cell Biol, 2012, 13 (12): 755- 766.
doi: 10.1038/nrm3478
15 Olsen SK , Capili AD , Lu X , et al. Active site remodelling accompanies thioester bond formation in the SUMO E1[J]. Nature, 2010, 463 (7283): 906- 912.
doi: 10.1038/nature08765
16 Gong L , Kamitani T , Fujise K , et al. Preferential interaction of sentrin with a ubiquitin-conjugating enzyme, Ubc9[J]. J Biol Chem, 1997, 272 (45): 28198- 28201.
doi: 10.1074/jbc.272.45.28198
17 Desterro JM , Thomson J , Hay RT . Ubch9 conjugates SUMO but not ubiquitin[J]. FEBS Lett, 1997, 417 (3): 297- 300.
doi: 10.1016/S0014-5793(97)01305-7
18 Rodriguez MS , Dargemont C , Hay RT . SUMO-1conjugation in vivo requires both a consensus modification motif and nuclear targeting[J]. J Biol Chem, 2001, 276 (16): 12654- 12659.
doi: 10.1074/jbc.M009476200
19 Johnson ES , Gupta AA . An E3-like factor that promotes SUMO conjugation to the yeast septins[J]. Cell, 2001, 106 (6): 735- 744.
doi: 10.1016/S0092-8674(01)00491-3
20 Gong L , Millas S , Maul GG , et al. Differential regulation of sentrinized proteins by a novel sentrin-specific protease[J]. J Biol Chem, 2000, 275 (5): 3355- 3359.
doi: 10.1074/jbc.275.5.3355
21 Schulz S , Chachami G , Kozaczkiewicz L , et al. Ubiquitin-specific protease-like 1(USPL1) is a SUMO isopeptidase with essential, non-catalytic functions[J]. EMBO Rep, 2012, 13 (10): 930- 938.
doi: 10.1038/embor.2012.125
22 Bellail AC , Olson JJ , Hao C . SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression[J]. Nature Commun, 2014, 5: 4234.
doi: 10.1038/ncomms5234
23 Yang W , Wang L , Roehn G , et al. Small ubiquitin-like modifier 1-3 conjugation[corrected] is activated in human astrocytic brain tumors and is required for glioblastoma cell survival[J]. Cancer Sci, 2013, 104 (1): 70- 77.
doi: 10.1111/cas.12047
24 Li H , Niu H , Peng Y , et al. Ubc9 promotes invasion and metastasis of lung cancer cells[J]. Oncol Rep, 2013, 29 (4): 1588- 1594.
doi: 10.3892/or.2013.2268
25 Shao DF , Wang XH , Li ZY , et al. High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer[J]. Am J Cancer Res, 2015, 5 (2): 140- 154.
26 Zhang H , Kuai X , Ji Z , et al. Over-expression of small ubiquitin-related modifier-1 and sumoylated p53 in colon cancer[J]. Cell Biochem Biophys, 2013, 67 (3): 1081- 1087.
doi: 10.1007/s12013-013-9612-x
27 Guo WH , Yuan LH , Xiao ZH , et al. Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma[J]. J Cancer Res Clin Oncol, 2011, 137 (3): 533- 541.
doi: 10.1007/s00432-010-0920-x
28 Chien W , Lee KL , Ding LW , et al. PIAS4 is an activator of hypoxia signaling via VHL suppression during growth of pancreatic cancer cells[J]. Br J Cancer, 2013, 109 (7): 1795- 1804.
doi: 10.1038/bjc.2013.531
29 Sternsdorf T , Jensen K , Will H . Evidence for covalent modification of the nuclear dot-associated proteins PML and Sp100 by PIC1/SUMO-1[J]. J Cell Biol, 1997, 139 (7): 1621- 1634.
doi: 10.1083/jcb.139.7.1621
30 Zhong S , Muller S , Ronchetti S , et al. Role of SUMO-1-modified PML in nuclear body formation[J]. Blood, 2000, 95 (9): 2748- 2752.
doi: 10.1182/blood.V95.9.2748.009k31a_2748_2752
31 Altmannova V , Kolesar P , Krejci L . SUMO wrestles with recombination[J]. Biomolecules, 2012, 2 (3): 350- 375.
doi: 10.3390/biom2030350
32 Bonne-Andrea C , Kahli M , Mechali F , et al. SUMO2/3 modification of cyclin E contributes to the control of replication origin firing[J]. Nat Commun, 2013, 4: 1850.
doi: 10.1038/ncomms2875
33 Carter S , Bischof O , Dejean A , et al. C-terminal modifications regulate MDM2 dissociation and nuclear export of p53[J]. Nat Cell Biol, 2007, 9 (4): 428- 435.
doi: 10.1038/ncb1562
34 Renner F , Moreno R , Schmitz ML . SUMOylation-dependent localization of IKKepsilon in PML nuclear bodies is essential for protection against DNA-damage-triggered cell death[J]. Mol Cell, 2010, 37 (4): 503- 515.
doi: 10.1016/j.molcel.2010.01.018
35 Potts PR , Yu H . The SMC5/6 complex maintains telomere length in ALT cancer cells through SUMOylation of telomere-binding proteins[J]. Nat Struct Mol Biol, 2007, 14 (7): 581- 590.
doi: 10.1038/nsmb1259
36 Li J , Xu Y , Long XD , et al. Cbx4 governs HIF-1alpha to potentiate angiogenesis of hepatocellular carcinoma by its SUMO E3 ligase activity[J]. Cancer Cell, 2014, 25 (1): 118- 131.
doi: 10.1016/j.ccr.2013.12.008
37 Cashman R , Cohen H , Ben-Hamo R , et al. SENP5 mediates breast cancer invasion via a TGFbetaRI SUMOylation cascade[J]. Oncotarget, 2014, 5 (4): 1071- 1082.
doi: 10.18632/oncotarget.1783
38 Mao H , Lebrun DG , Yang J , et al. Deregulated signaling pathways in glioblastoma multiforme: Molecular mechanisms and therapeutic targets[J]. Cancer Invest, 2012, 30 (1): 48- 56.
doi: 10.3109/07357907.2011.630050
39 Soares IN , Caetano FA , Pinder J , et al. Regulation of stress-inducible phosphoprotein 1 nuclear retention by protein inhibitor of activated STAT PIAS1[J]. Mol Cell Proteomics, 2013, 12 (11): 3253- 3270.
doi: 10.1074/mcp.M113.031005
40 Nakayama KI , Nakayama K . Ubiquitin ligases: Cell-cycle control and cancer[J]. Nat Rev Cancer, 2006, 6 (5): 369- 381.
doi: 10.1038/nrc1881
41 Bernstock JD , Ye D , Gessler FA , et al. Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming[J]. Sci Rep, 2017, 7 (1): 7425.
42 Xu H , Rahimpour S , Nesvick CL , et al. Activation of hypoxia signaling induces phenotypic transformation of glioma cells: Implications for bevacizumab antiangiogenic therapy[J]. Oncotarget, 2015, 6 (14): 11882- 11893.
doi: 10.18632/oncotarget.3592
43 Yang Y , Xia Z , Wang X , et al. Small-molecule inhibitors targeting protein sumoylation as novel anticancer compounds[J]. Mol Pharmcol, 2018, 94 (2): 885- 894.
doi: 10.1124/mol.118.112300
44 Chen Y , Wen D , Huang Z , et al. 2-(4-Chlorophenyl)-2-oxoethyl 4-benzamidobenzoate derivatives, a novel class of SENP1 inhibitors: virtual screening, synthesis and biological evaluation[J]. Bioorg Med Chem Lett, 2012, 22 (22): 6867- 6870.
doi: 10.1016/j.bmcl.2012.09.037
45 Brave M , Dagher R , Farrell A , et al. Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer[J]. J Oncol, 2006, 20 (11): 1401- 1404.
46 Pommier Y . Topoisomerase I inhibitors: camptothecins and beyond[J]. J Nat Rev Cancer, 2006, 6 (10): 789.
doi: 10.1038/nrc1977
47 Ling YH , Donato NJ , Perez-Soler R . Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines[J]. Cancer Chemother Pharmacol, 2001, 47 (6): 473- 480.
doi: 10.1007/s002800000239
48 Hirohama M , Kumar A , Fukuda I , et al. Spectomycin B1 as a novel SUMOylation inhibitor that directly binds to SUMO E2[J]. ACS Chem Biol, 2013, 8 (12): 2635- 2642.
doi: 10.1021/cb400630z
49 Schneekloth JS Jr . Drug discovery: controlling protein SUMOylation[J]. Nat Chem Biol, 2017, 13 (11): 1141.
doi: 10.1038/nchembio.2496
50 Fukuda I , Ito A , Hirai G , et al. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate[J]. Chem Biol, 2009, 16 (2): 133- 140.
doi: 10.1016/j.chembiol.2009.01.009
51 Fukuda I , Ito A , Uramoto M , et al. Kerriamycin B inhibits protein SUMOylation[J]. J Antibiot, 2009, 62 (4): 221.
doi: 10.1038/ja.2009.10
52 Takemoto M , Kawamura Y , Hirohama M , et al. Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrata[J]. J Antibiot, 2014, 67 (4): 335.
doi: 10.1038/ja.2013.142
53 Suzawa M , Miranda DA , Ramos KA , et al. A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver[J]. Elife, 2015, 4: e09003.
doi: 10.7554/eLife.09003
54 Zhao B , Villhauer EB , Bhuripanyo K , et al. SUMO-mimicking peptides inhibiting protein SUMOylation[J]. Chembiochem, 2014, 15 (18): 2662- 2666.
doi: 10.1002/cbic.201402472
55 Wu J , Lei H , Zhang J , et al. Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation[J]. Oncotarget, 2016, 7 (37): 58995- 59005.
doi: 10.18632/oncotarget.10636
56 Bernstock JD , Lee Y , Peruzzotti-Jametti L , et al. A novel quantitative high-throughput screen identifies drugs that both activate SUMO conjugation via the inhibition of microRNAs 182 and 183 and facilitate neuroprotection in a model of oxygen and glucose deprivation[J]. J Cereb Blood Flow Metab, 2016, 36 (2): 426- 441.
doi: 10.1177/0271678X15609939
57 Huang W , He T , Chai C , et al. Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression[J]. PLoS One, 2012, 7 (5): e37693.
doi: 10.1371/journal.pone.0037693
[1] 王琳琳 孙美丽 孙玉萍 张楠 刘传勇. 中心体α-微管蛋白、γ-微管蛋白在脑胶质瘤中的表达及其与Survivin表达的相关性研究[J]. 山东大学学报(医学版), 2209, 47(6): 103-.
[2] 郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[3] 杨闯,张荣雨,宋彬,王程君,赵文,玄甜甜,李际盛. 阿美替尼一线治疗EGFR突变肺腺癌伴大疱性类天疱疮1例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(12): 32-37.
[4] 李夕凤,李红梅. 脑脊液CXCL10:抗NMDAR脑炎潜在的生物学标志物[J]. 山东大学学报 (医学版), 2023, 61(6): 47-52.
[5] 朱正阳,沈靖菲,陈思璇,叶梅萍,杨惠泉,周佳南,梁雪,张鑫,张冰. 磁敏感加权成像不同影像组学模型预测胶质瘤IDH基因突变[J]. 山东大学学报 (医学版), 2023, 61(12): 44-50.
[6] 王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[7] 李华玉,时萧寒,张新蕊,李峰. 203例胶质瘤患者睡眠障碍与炎症细胞因子的关联分析[J]. 山东大学学报 (医学版), 2022, 60(12): 26-30.
[8] 哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[9] 孙庆杰,张怡莎,管尚慧,凤志慧. 丙戊酸对134例放疗神经胶质瘤患者预后生存和肿瘤复发的影响[J]. 山东大学学报 (医学版), 2021, 59(8): 80-85.
[10] 顾金海,路宁,顾珈榕,文玉军,强媛媛,和祯泉,杨勇,王峰,孙涛,牛建国. 胶质瘤细胞与血管内皮细胞的信号Crosstalk对肿瘤细胞增殖和侵袭的影响[J]. 山东大学学报 (医学版), 2021, 59(2): 1-6.
[11] 宋珍珍,孙小玲,李海鸥,王芳,张冉,于德新. 120例胶质瘤及瘤周水肿MRI影像组学在评估肿瘤复发中的价值[J]. 山东大学学报 (医学版), 2021, 59(11): 53-60.
[12] 李文清,叶兰,姜玉华. CDK7抑制剂THZ1对人胶质瘤细胞U251放疗的增敏性[J]. 山东大学学报 (医学版), 2021, 59(1): 8-13.
[13] 李刚,薛皓,邱伟,赵荣荣. 脑胶质瘤抑制性免疫微环境形成机制及研究进展[J]. 山东大学学报 (医学版), 2020, 1(8): 67-73.
[14] 吴强,何泽鲲,刘琚,崔晓萌,孙双,石伟. 基于机器学习的脑胶质瘤多模态影像分析[J]. 山东大学学报 (医学版), 2020, 1(8): 81-87.
[15] 焉传祝,王伟,纪坤乾,赵玉英. 线粒体与脑疾病[J]. 山东大学学报 (医学版), 2020, 1(8): 34-41.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发